Generics 12

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Ambrisentan manufacturers

12 products found

Filters

12 products found

ambrisentan

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Chile
Available for
Licensing with supply, Distribution only
Comments
Ref: Volibris ®
Manufacturer #337
A pharmaceutical manufacturer based in the EU that has been active in 90+ countries selling its products in the EU, Africa, North America, Middle East, and Asia for 30+ years. Key production lines are Rx and OTC. Main therapeutic areas include diabetes, CNS, and dermatology. The company's production lines are GMP-compliant. The company possesses branches in the Middle East and Asia.

Manufacturer usually replies in 5 days

ambrisentan

Tablets 5 mg ,10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Volibris® (GSK)
Manufacturer #10578
This pharmaceutical company, operating for several decades, is a prominent player in the European market. Their core focus is on generic and biosimilar medications, catering to a broad spectrum of healthcare needs. Their product portfolio includes prescription drugs, over-the-counter medications, and health and nutrition supplements. Their offerings are available in various dosage forms, including solids, injectables, and liquids. The company holds a strong track record in the industry, with GMP certifications for their production lines in the EU and North America. They also engage in manufacturing for other pharmaceutical companies. Key therapy areas covered by their products include cardiology, oncology, and women's health. Their dedication to quality and extensive product range position them as a leading force in the pharmaceutical landscape.

Manufacturer usually replies in 8 days

ambrisentan

Tablets, film coated 2.5 mg, 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply, Technology transfer
Manufacturer #260
Pharmaceutical manufacturer operating in the EU for 50+ years. Activities include scientific development, manufacturing, out-licensing, marketing, and distribution of high-quality generic medicines. The company owns several production facilities that all comply with EU GMP requirements. Key dosage forms include conventional solids, cytostatic injectables, and cytostatic orals. The company holds an in-house R&D and Intellectual property business unit, as well as a regulatory affairs team that prepares CTD dossiers and maintains direct contact with regulatory agencies worldwide. The portfolio includes more than three thousand MA sets approved in the EU while hundreds of MA are in progress. Key therapy lines are cardiovascular, CNS, diabetes, immunology, oncology, and more. The company is active in nearly 100 countries worldwide, selling its products in Africa, Asia, Australia, Europe, LATAM, and the Middle East.

Manufacturer usually replies in 12 days

Want to see all 12 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

What is the Ambrisentan drug?

Ambrisentan is an endothelin receptor antagonist. Ambrisentan will act by relaxing the muscles that are constricted in blood vessels by the peptide endothelin and causing blood pressure. Ambrisentan drug is used to treat PAH (Pulmonary Artery Hypertension); it means high blood pressure in the lungs. Taking Ambristentan medicine is not only to treat pulmonary hypertension but also to improve the exercise ability of the patient.
The FDA approved Ambrisentan in 2007 and the European Medicines Agency. It is considered as an orphan drug.

Ambrisentan manufacturers and wholesalers:

Ambrisentan is known under different brand names; probably, the most known is Letairis from the manufacturer Gilead in the US. In the EU, the brand name is Volibris, in India Pulmonext by the MSN Labs, Ambrican by Lupin, Endobloc by Cipla Ltd, and in Germany, the brand name is Zambri by German Remedies Ltd.
The FDA approved the Ambrisentan generic to four manufacturers: Mylan Pharmaceuticals, Watson Laboratories, Sun Pharma Global, and Zydus Pharmaceuticals. The Ambrisentan drug is found globally.
Ambrisentan suppliers market it in the form of oral tablets of 5 mg and 10 mg.

Ambrisentan for sales:

In the US, Ambrisentan under the name Letairis can cost from $233.27 to $258.55 per oral tablet of 5 mg or 10mg. In France, Ambrisentan, under the name Volibris, costs around 72 € without tax per tablet.
As Ambrisentan is available globally, fraudulent online pharmacies may attempt to sell an illegal generic version of Ambrisentan. Thanks to Pipelinepharma online marketplace, you can be sure of the qualifications of the sellers because they all have been through quality control procedures. Plus, being sure your future partner is qualified, you will save time sourcing for the product and buyer or seller, because it is all in one safe place: Pipelinepharma B2B marketplace. On the platform, you can easily place orders for any pharmaceutical products, including Ambrisentan. From our online marketplace, Ambrisentan is mostly available from the European Union (the Czech Republic and Greece) and Argentina.

How to use Ambrisentan drugs?

To treat PAH, an adult should take the initial dose of 5 mg of Ambrisentan orally once a day. A pregnant woman or a woman who is planning to get pregnant should avoid at all costs taking the Ambrisentan drug because it can cause severe birth defects.
Taking Ambrisentan can have some side effects, the most common ones are: bloating or swelling of the face, arms, hands, lower legs, or feet, rapid weight gain, tingling of the hands or feet, unusual weight gain or loss.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation